57 related articles for article (PubMed ID: 7710452)
1. Pharmacokinetic drug interaction between epirubicin and interferon-alpha-2b in serum and red blood cells.
Bandak S; Czejka M; Schüller J; Schernhammer E
Arzneimittelforschung; 1995 Feb; 45(2):212-5. PubMed ID: 7710452
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo binding of epirubicin to red blood cells and human plasma proteins.
Bandak S; Czejka M; Schüller J
Z Naturforsch C J Biosci; 1994; 49(7-8):483-8. PubMed ID: 7945673
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic interaction between 4'-epidoxorubicin and the multidrug resistance reverting agent quinine.
Czejka M; Bandak S; Simon D; Schüller J; Weiss C; Schernhammer E
Z Naturforsch C J Biosci; 1995; 50(7-8):565-70. PubMed ID: 7546045
[TBL] [Abstract][Full Text] [Related]
4. [Binding of epirubicin to human plasma protein and erythrocytes: interaction with the cytoprotective amifostine].
Pernkopf I; Tesch G; Dempe K; Kletzl H; Schüller J; Czejka M
Pharmazie; 1996 Nov; 51(11):897-901. PubMed ID: 9036391
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic aspects of interferon alfa-2b after intrahepatic or intraperitoneal administration.
Schüller J; Czejka MJ; Schernthaner G; Wirth M; Bosse C; Jäger W; Micksche M
Semin Oncol; 1992 Apr; 19(2 Suppl 3):98-104. PubMed ID: 1557662
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and toxicity of two schedules of high dose epirubicin.
Tjuljandin SA; Doig RG; Sobol MM; Watson DM; Sheridan WP; Morstyn G; Mihaly G; Green MD
Cancer Res; 1990 Aug; 50(16):5095-101. PubMed ID: 2379173
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic and pharmacodynamic characterization of a new formulation containing synergistic proportions of interferons alpha-2b and gamma (HeberPAG) in patients with mycosis fungoides: an open-label trial.
García-Vega Y; García-García I; Collazo-Caballero SE; Santely-Pravia EE; Cruz-Ramírez A; Tuero-Iglesias AD; Alfonso-Alvarado C; Cabrera-Placeres M; Castro-Basart N; Duncan-Roberts Y; Carballo-Treto TI; Soto-Matos J; Izquierdo-Toledo Y; Vázquez-Blomquist D; García-Iglesias E; Bello-Rivero I
BMC Pharmacol Toxicol; 2012 Dec; 13():20. PubMed ID: 23272809
[TBL] [Abstract][Full Text] [Related]
8. Disposition of 5-formyl- and 5-methyltetrahydrofolic acid in serum after i.v. bolus of calcium folinate: pharmacokinetic drug interaction with preadministered interferon-alpha-2b.
Czejka MJ; Schüller J; Weiss C; Bandak S; Meyer B; Simon D
Eur J Drug Metab Pharmacokinet; 1995; 20(4):255-62. PubMed ID: 8983929
[TBL] [Abstract][Full Text] [Related]
9. Multiple-dose pharmacokinetics of epirubicin at four different dose levels: studies in patients with metastatic breast cancer.
Jakobsen P; Steiness E; Bastholt L; Dalmark M; Lorenzen A; Petersen D; Gjedde SB; Sandberg E; Rose C; Nielsen OS
Cancer Chemother Pharmacol; 1991; 28(1):63-8. PubMed ID: 2040035
[TBL] [Abstract][Full Text] [Related]
10. Clinical pharmacokinetics of epirubicin.
Robert J
Clin Pharmacokinet; 1994 Jun; 26(6):428-38. PubMed ID: 8070217
[TBL] [Abstract][Full Text] [Related]
11. A phase I trial of interferon alpha-2b with folinic acid and 5-fluorouracil administered by 4-hour infusion in metastatic colorectal carcinoma.
Kreuser ED; Hilgenfeld RU; Matthias M; Hoksch B; Boewer C; Oldenkott B; Knauf WU; Boese-Landgraf J; Schalhorn A; Zeitz M
Semin Oncol; 1992 Apr; 19(2 Suppl 3):197-203. PubMed ID: 1557647
[TBL] [Abstract][Full Text] [Related]
12. A Phase I/II study evaluating escalating doses of recombinant human albumin-interferon-alpha fusion protein in chronic hepatitis C patients who have failed previous interferon-alpha-based therapy.
Balan V; Nelson DR; Sulkowski MS; Everson GT; Lambiase LR; Wiesner RH; Dickson RC; Post AB; Redfield RR; Davis GL; Neumann AU; Osborn BL; Freimuth WW; Subramanian GM
Antivir Ther; 2006; 11(1):35-45. PubMed ID: 16518958
[TBL] [Abstract][Full Text] [Related]
13. A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients.
Bain VG; Kaita KD; Yoshida EM; Swain MG; Heathcote EJ; Neumann AU; Fiscella M; Yu R; Osborn BL; Cronin PW; Freimuth WW; McHutchison JG; Subramanian GM
J Hepatol; 2006 Apr; 44(4):671-8. PubMed ID: 16487617
[TBL] [Abstract][Full Text] [Related]
14. Factors affecting epirubicin pharmacokinetics and toxicity: evidence against using body-surface area for dose calculation.
Gurney HP; Ackland S; Gebski V; Farrell G
J Clin Oncol; 1998 Jul; 16(7):2299-304. PubMed ID: 9667243
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 3rd Communication: suppositories.
Lintz W; Barth H; Osterloh G; Schmidt-Böthelt E
Arzneimittelforschung; 1998 Sep; 48(9):889-99. PubMed ID: 9793614
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of an extended-release human interferon alpha-2b formulation.
Bonetti A; Kim S
Cancer Chemother Pharmacol; 1993; 33(3):258-61. PubMed ID: 8269608
[TBL] [Abstract][Full Text] [Related]
17. [Pharmacokinetic aspects of dosage increase of recombinant interferon alpha-2B in patients following intraperitoneal and intra-arterial application].
Schüller J; Wirth M; Bosse C; Fogl U; Schernthaner G; Czejka MJ; Micksche M
Wien Klin Wochenschr; 1990 Dec; 102(24):717-20. PubMed ID: 2281675
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and metabolism of epirubicin administered as i.v. bolus and 48-h infusion in patients with advanced soft-tissue sarcoma.
Robert J; Bui NB
Ann Oncol; 1992 Sep; 3(8):651-6. PubMed ID: 1450047
[TBL] [Abstract][Full Text] [Related]
19. Epirubicin metabolism and pharmacokinetics after conventional- and high-dose intravenous administration: a cross-over study.
Camaggi CM; Strocchi E; Carisi P; Martoni A; Melotti B; Pannuti F
Cancer Chemother Pharmacol; 1993; 32(4):301-9. PubMed ID: 8324872
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 2nd communication: drops with ethanol.
Lintz W; Barth H; Becker R; Frankus E; Schmidt-Böthelt E
Arzneimittelforschung; 1998 May; 48(5):436-45. PubMed ID: 9638309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
